I have a dollar bill that was autographed by Neil Armstrong, Bob Hope, and Les Browne (Bob's band leader) in December 1969 when they were on the U.S.O. Christmas tour in Vietnam. I imagine it's a "one-of-a-kind".
Any idea what it might be worth?
Yellen isn't going to risk tanking the economy. Obama's approval rating is at an all time low.
The best opportunity for substantial profits from a penny stock. Currently under a nickle. Buy a few shares today and hold them for six months.
Jason Napadano says it's a "BUY" and worth five times the current share price.
Follow AMBS on Twitter: @AmarantusBio .... 8,606 followers
Micro cap bio-tech with tremendous potential.
Share price need to reach .10 for warrants to convert to provide additional funding.
Follow the company on Twitter.
"AMBS" - Buy a few shares under a nickle and hold them for six months.
Jason Napadano says it's currently a "BUY" and is worth .20.
Follow the company on Twitter: @AmarantusBio
China will be the new Hunt Brothers as it corners the market on gold. It's goal is to make China's currency the global standard replacing the U.S. dollars. Gold could triple in price in the next three years.
The Chinese are long term planners. Their time frame is longer than the next reporting period.
Zack's analyst, Jason Napadano, has a "buy rating" on AMBS with a price target of .20 or about 400% upside.
Read the recent Yahoo news.
Buy a few shares and hold them for a year.
If so then go buy a few shares of "AMBS" and hold them for a year. Zack's bio-tech analyst, Jason Napadano, recently placed a "BUY" rating on the stock with a .20 price target. One of the few times he's ever recommended buying a penny stock. Read the recent Yahoo news.
Deal with Becton Dickinson is in the works.
Follow the company on Twitter: @AmarantusBio .... 8,587 followers
Our initial article on LymPro back in April 2013 outlined our belief that the diagnostic division at Amarantus, which includes earlier-stage product, NuroPro for the diagnosis of Parkinson's disease, is worth $50 million in value. We think MANF is worth $40 million in value, as outlined in our initiation report from May 2013. Thus, we think Amarantus is worth $90 million today, and that represents over 200% upside from today - or a target price of $0.20 per share.